163 related articles for article (PubMed ID: 29251621)
41. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.
Fehse B; Chukhlovin A; Kühlcke K; Marinetz O; Vorwig O; Renges H; Krüger W; Zabelina T; Dudina O; Finckenstein FG; Kröger N; Kabisch H; Hochhaus A; Zander AR
J Hematother Stem Cell Res; 2001 Jun; 10(3):419-25. PubMed ID: 11454317
[TBL] [Abstract][Full Text] [Related]
42. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
43. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.
Zhao XS; Yan CH; Liu DH; Xu LP; Liu YR; Liu KY; Qin YZ; Wang Y; Huang XJ
Ann Hematol; 2013 Aug; 92(8):1111-9. PubMed ID: 23680867
[TBL] [Abstract][Full Text] [Related]
44. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
45. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
46. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
47. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.
Shimoni A; Nagler A; Kaplinsky C; Reichart M; Avigdor A; Hardan I; Yeshurun M; Daniely M; Zilberstein Y; Amariglio N; Brok-Simoni F; Rechavi G; Trakhtenbrot L
Leukemia; 2002 Aug; 16(8):1413-8; discussion 1419-22. PubMed ID: 12145678
[TBL] [Abstract][Full Text] [Related]
48. [Correlation between clinical outcome and WT1 detection after hematopoietic stem cell transplantation in acute leukemia].
Zhao BR; Tang XW; Cen JN; Jin S; Shi XL; Wei XA; Chang WR; Sun AN; Wu DP
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1375-8. PubMed ID: 21756806
[TBL] [Abstract][Full Text] [Related]
49. [Clinical significance of dynamic monitoring of cell chimerism following allogeneic hematopoietic stem cell transplantation].
Jiang Y; Wan LP; Wang C; Yan SK; Gao YR; Jiang JL; Yang J; Cai Y; Bai HT; Wei DL; Xie KC
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):667-71. PubMed ID: 19176059
[TBL] [Abstract][Full Text] [Related]
50. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
[TBL] [Abstract][Full Text] [Related]
51. [Chimerism analysis after hematopoietic cell transplantation: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Dubois V; Alizadeh M; Bourhis JH; Etancelin P; Farchi O; Ferrand C; Goursaud L; Mollet I; Renac V; Varlet P; Yakoub-Agha I; Bay JO
Bull Cancer; 2017 Dec; 104(12S):S59-S64. PubMed ID: 29128084
[TBL] [Abstract][Full Text] [Related]
52. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
53. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
[TBL] [Abstract][Full Text] [Related]
54. [Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Yafour N; Beckerich F; Bulabois CE; Chevallier P; Daguindau É; Dumesnil C; Guillaume T; Huynh A; Levrat SM; Menard AL; Michallet M; Pautas C; Poiré X; Ravinet A; Yakoub-Agha I; Bazarbachi A
Bull Cancer; 2017 Dec; 104(12S):S84-S98. PubMed ID: 29179894
[TBL] [Abstract][Full Text] [Related]
55. Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies.
Le Bris Y; Costes D; Bourgade R; Guillaume T; Peterlin P; Garnier A; Le Bourgeois A; Chevallier P; Béné MC
Bone Marrow Transplant; 2022 Sep; 57(9):1435-1441. PubMed ID: 35764681
[TBL] [Abstract][Full Text] [Related]
56. Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation.
Elmaagacli AH; Beelen DW; Becks HW; Mobascher A; Stockova J; Trzensky S; Opalka B; Schaefer UW
Bone Marrow Transplant; 1996 Aug; 18(2):397-403. PubMed ID: 8864452
[TBL] [Abstract][Full Text] [Related]
57. [Significance of quantitative detection of bcr-abl mRNA in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplant].
Geng SX; DU X; Weng JY; Li QH; Su JH; Lin QX; Li YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):993-7. PubMed ID: 17956677
[TBL] [Abstract][Full Text] [Related]
58. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms.
Suttorp M; Schmitz N; Dreger P; Schaub J; Löffler H
Leukemia; 1993 May; 7(5):679-87. PubMed ID: 8097800
[TBL] [Abstract][Full Text] [Related]
59. Quantitative assessment of hematopoietic chimerism by quantitative real-time polymerase chain reaction of sequence polymorphism systems after hematopoietic stem cell transplantation.
Qin XY; Li GX; Qin YZ; Wang Y; Wang FR; Liu DH; Xu LP; Chen H; Han W; Wang JZ; Zhang XH; Li JL; Li LD; Liu KY; Huang XJ
Chin Med J (Engl); 2011 Aug; 124(15):2301-8. PubMed ID: 22029079
[TBL] [Abstract][Full Text] [Related]
60. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation.
Thiede C; Bornhäuser M; Ehninger G
Acta Haematol; 2004; 112(1-2):16-23. PubMed ID: 15179000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
